Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Richard Glickman, Aurinia’s Chief Executive Officer, will provide a corporate overview during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
If you are an institutional investor, and would like to attend the presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting.
Event: H. C. Wainwright Annual Global Life Sciences Conference
Date: April 10, 2018
Time: 9:00am CET
Location: Salon Atlantic-W; Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
The presentation will be webcast live. To access the webcast, please visit www.hcwevents.com. A replay will remain available for 90 days following the live presentation.
Aurinia is a clinical stage biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are suffering from serious diseases with a high unmet medical need. The company is currently developing voclosporin, an investigational drug, for the treatment of LN, FSGS, and DES. The company is headquartered in Victoria, BC and focuses its development efforts globally. For further information, see our website at www.auriniapharma.com.
We seek safe harbor.